Skin cholesterol as measured by the PREVU test had previously proved to be associated with the presence and extent of coronary artery disease in patients with angina or a positive exercise stress test.
The PREVU test doesn't require a blood draw, pretest fasting, or a skin biopsy.
3 September 2010 - Canada-based medical diagnostic company Miraculins Inc (CVE: MOM) announced today it has completed the acquisition from PreMD Inc of all assets relating to the PREVU Skin Cholesterol Test.
PREVU is a simple, non-invasive test that addresses the worldwide market of cardiovascular risk assessment.
and Canada, IMI says it is developing a consumer version of the product which will be branded PREVU Home Test and would be available in retail pharmacies.
McNeil is a leading consumer health care company with a global network, and we are pleased to partner with them to maximize the commercial opportunity for PREVU.